People Background Check
Find People:

Amelia BlackFremont, CA

Get Report

Amelia Black Phones & Addresses

Fremont, CA

Mentions for Amelia Black

Amelia Black resumes & CV records

Resumes

Amelia Black Photo 32

Equipment Sales Representative

Work:

Equipment Sales Representative
Amelia Black Photo 33

Amelia Black

Amelia Black Photo 34

Head Of Outbound Marketing

Work:

Head of Outbound Marketing
Amelia Black Photo 35

Amelia Black

Publications & IP owners

Us Patents

Treating Autoimmune Diseases With Humanized Anti-Cd40L Antibody

US Patent:
7122187, Oct 17, 2006
Filed:
Jun 17, 2002
Appl. No.:
10/171681
Inventors:
Amelia Black - Los Gatos CA, US
Nabil Hanna - Rancho Santa Fee CA, US
Eduardo A. Padian - Kensington MD, US
Roland A. Newman - San Diego CA, US
Assignee:
Biogen IDEC Inc. - Cambridge MA
International Classification:
A61K 39/395
C07K 16/28
US Classification:
4241541, 4241301, 4241331, 4241411, 4241431, 4241441, 4241531, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873, 53038775
Abstract:
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.

Expression Vector

US Patent:
7674618, Mar 9, 2010
Filed:
Sep 3, 2004
Appl. No.:
10/934304
Inventors:
Amelia Black - Los Gatos CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
C12N 15/00
C12N 15/10
C12N 16/65
C12N 15/79
US Classification:
4353201, 536 241, 536 231, 536 232, 435 691, 435325
Abstract:
This invention provides nucleic acids and expression vectors, and host cells transformed with the same, for providing high expression of a desired polypeptide. Also provided are methods of using the expression vectors, nucleic acids, and host cells which have been modified by these compositions, for increasing expression of a gene encoding a desired polypeptide.

Transgenic Animals Expressing Chimeric Antibodies For Use In Preparing Human Antibodies

US Patent:
7910798, Mar 22, 2011
Filed:
Mar 30, 2007
Appl. No.:
12/295557
Inventors:
Dawn M. Tanamachi - San Carlos CA, US
Peter Brams - Sacramento CA, US
Amelia Black - Los Gatos CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
A01K 67/027
C12P 21/08
C07H 21/04
US Classification:
800 18, 800 6, 536 2353
Abstract:
The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.

Transgenic Animals Expressing Chimeric Antibodies For Use In Preparing Human Antibodies

US Patent:
8232449, Jul 31, 2012
Filed:
Feb 17, 2011
Appl. No.:
13/029186
Inventors:
Dawn M. Tanamachi - San Carlos CA, US
Peter Brams - Sacramento CA, US
Amelia Black - Los Gatos CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
A01K 67/027
C12P 21/08
C07H 21/04
US Classification:
800 18, 800 6, 536 2353
Abstract:
The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.

Monoclonal Antibodies Against Cd30 Lacking In Fucosyl Residues

US Patent:
8491898, Jul 23, 2013
Filed:
May 2, 2012
Appl. No.:
13/462566
Inventors:
Josephine M. Cardarelli - San Carlos CA, US
Amelia Nancy Black - Los Gatos CA, US
Assignee:
Medarex, L.L.C. - Princeton NJ
International Classification:
A61K 39/395
A61K 39/44
US Classification:
4241331, 4241411, 4241431, 4241441, 4241781
Abstract:
The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.

Monoclonal Antibodies Against Cd30 Lacking In Fucosyl Residues

US Patent:
8207303, Jun 26, 2012
Filed:
Feb 17, 2006
Appl. No.:
11/918178
Inventors:
Josephine M. Cardarelli - San Carlos CA, US
Amelia Nancy Black - Los Gatos CA, US
Assignee:
Medarex, Inc. - Princeton NJ
International Classification:
C07K 16/00
C07K 16/46
C07K 16/28
A61K 39/395
US Classification:
5303871, 5303873, 53038822, 5303887, 4241301, 4241331, 4241431, 4241531
Abstract:
The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.

Treating Autoimmune Diseases With Humanized Anti-Cd401 Antibodies

US Patent:
2006015, Jul 13, 2006
Filed:
Mar 9, 2006
Appl. No.:
11/370898
Inventors:
Amelia Black - Los Gatos CA, US
Nabil Hanna - Rancho Santa Fe CA, US
Eduardo Padlan - Kensington MD, US
Roland Newman - San Diego CA, US
International Classification:
A61K 39/395
C07K 16/44
US Classification:
424133100, 530388150
Abstract:
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.

Monoclonal Antibodies Against Cd30 Lacking In Fucosyl And Xylosyl Residues

US Patent:
2009017, Jul 9, 2009
Filed:
Jan 17, 2007
Appl. No.:
12/160990
Inventors:
Amelia Naucy Black - Los Gatos CA, US
David B. Passmore - San Carlos CA, US
Mohan Srinivasan - Cupertino CA, US
Lynn F. Dickey - Cary NC, US
Kevin M. Cox - Raleigh NC, US
Charles G. Peele - Apex NC, US
Ming-Bo Wang - Canberra, AU
Assignee:
MEDAREX, INC. - Princeton NJ
International Classification:
C07K 16/46
C12N 5/04
C12N 5/06
A61K 39/395
A61P 35/00
US Classification:
4241781, 530395, 435419, 435375
Abstract:
The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the growth of CD30 cells, such as tumor cells, are also provided.

Possible Relatives

Cynthia E Black  Dawn L Black  Deana D Black  Dallas B Black  Dalton Black  Debby L Black  Damon G Black  Amelia D Johnson  Amelia L Johnston  Amelia T Stanford 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.